文献速递肝病

TTC39B通过降解pRb促进肝脏脂肪生成并存在性别差异

TTC39B destabilizes retinoblastoma protein promoting hepatic lipogenesis in a sex-specific fashion.
PubMed 文献 · J Hepatol · 2021-09-30

本研究探讨TTC39B(T39)通过泛素化降解pRb调控肝脏脂质合成基因的分子机制及性别差异。在雌鼠中,T39缺失以pRb/E2F1依赖方式降低脂合成基因(尤其Pnpla3)表达;雄鼠中该效应较弱且不依赖pRb/E2F1。T39还通过VAPB/SCAP通路影响脂合成,且此通路在两性中均起作用。

要点

  • T39通过C端TPR结构域与pRb结合并促进其蛋白酶体降解。
  • 雌性中T39缺失经pRb/E2F1降低Pnpla3等脂合成基因,雄性此效应弱且不依赖pRb/E2F1。
  • T39抑制可能成为女性NAFLD下调PNPLA3的新策略。

核心结论

  • T39通过pRb/E2F1(雌性特异性)和VAPB/SCAP(两性共有)通路调控肝脏脂合成基因,存在性别二态性。
  • 抑制T39可下调PNPLA3,可能作为女性NAFLD治疗新策略。

研究设计与样本

  • 在HEK293A细胞中验证T39/pRb相互作用;在饮食诱导NAFLD小鼠(pRb或E2F1缺陷)及原代人肝细胞中采用反义寡核苷酸(ASO)敲低T39。

主要发现

  • T39经C端TPR结构域与pRb结合并促进其蛋白酶体降解。
  • 雌鼠中T39缺失以pRb/E2F1依赖方式降低脂合成基因mRNA(尤其Pnpla3);雄鼠中降低幅度小且不依赖pRb/E2F1。
  • T39经N端FFAT基序与VAPB互作并稳定VAPB-SCAP结合;两性中T39敲低均不依赖pRb降低SCAP。
  • 卵巢切除消除T39敲低对肝脏pRb/E2F1/Pnpla3轴的影响。
  • 原代人肝细胞中,T39敲低降低女性(而非男性)PNPLA3等脂合成基因表达。

临床怎么用

  • T39抑制可能作为下调PNPLA3、治疗NAFLD(尤其女性)的潜在策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Molecular mechanisms underlying the different susceptibility of men and women to non-alcoholic fatty liver disease (NAFLD) are poorly understood. The TTC39B locus encodes a scaffolding protein, associates with gynecological disorders and its deletion protects mice from diet-induced steatohepatitis. This study aimed to elucidate the molecular mechanisms linking TTC39B (T39) to the expression of lipogenic genes and to explore sex-specific effects. METHODS: Co-expression in HEK293A cells validated the novel T39/pRb interaction predicted by a protein-protein interaction algorithm. T39 was knocked down using an antisense oligonucleotide (ASO) in mice with dietary NAFLD and a genetic deficiency of pRb or its downstream effector E2F1, as well as in primary human hepatocytes. RESULTS: T39 interacts with pRb via its C-terminal TPR domain and promotes its proteasomal degradation. In female mice, T39 deficiency reduces the mRNA of lipogenic genes, especially Pnpla3, in a pRb- and E2F1-dependent manner. In contrast, in male mice, T39 deficiency results in a much smaller reduction in lipogenic gene expression that is independent of pRb/E2F1. T39 also interacts with VAPB via an N-terminal FFAT motif and stabilizes the interaction of VAPB with SCAP. Ovariectomy abolishes the effect of T39 knockdown on the hepatic pRb/E2F1/Pnpla3 axis. In both sexes T39 knockdown reduces SCAP independently of pRb. In primary human hepatocytes, T39 knockdown reduces expression of PNPLA3 and other lipogenic genes in women but not men. CONCLUSIONS: We have uncovered a conserved sexual dimorphism in the regulation of hepatic lipogenic genes, with effects of T39 mediated through pRb/E2F1 in females and VAPB/SCAP in both sexes. T39 inhibition could be a novel strategy to downregulate PNPLA3 and treat NAFLD in women. LAY SUMMARY: In females, the protein TTC39B degrades a tumor suppressor in the liver to promote the synthesis of new fat and the expression of a major genetic risk factor for non-alcoholic fatty liver disease. TTC39B is a potential therapeutic target for non-alcoholic fatty liver disease, especially in women.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Hsieh J, Molusky MM, McCabe KM, et al. TTC39B destabilizes retinoblastoma protein promoting hepatic lipogenesis in a sex-specific fashion. J Hepatol. 2021. PMID: 34600974. doi:10.1016/j.jhep.2021.09.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。